此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Healthy Volunteer Study to Evaluate the Impact of Various Common Interventions on Venous Pressure Signal Captured by PIVA

2021年3月29日 更新者:Baxter Healthcare Corporation

Healthy Volunteer Study to Evaluate the Impact of Various Common Interventions on Venous Pressure Signal Captured by Peripheral Intravenous Analysis (PIVA) Technology

Non-invasive sensors have been used in research in the United States (US) to aid in the assessment of a subject's heart rate (HR), respiratory rate (RR) and fluid volume status. This estimate and its trended value over time, when used along with clinical signs and symptoms and other subject test results, can aid in the process of reaching a diagnosis and formulating a therapeutic plan when abnormalities of volume status, or RR are suspected.

Non-invasive sensors like the Peripheral IntraVenous Analysis (PIVA) sensor under development by Baxter and the Deltran blood pressure (BP) transducer, capture waveforms created by physiological mechanisms such as blood flow and breathing. An algorithm is then applied to the captured waveform to give clinicians an idea of hemodynamic (volume) status, and RR.

In this study, the functional robustness (e.g., subjects sitting, elevated leg positions, etc.) of the PIVA algorithm/technology will be demonstrated by evaluating the impact of various common interventions on the venous pressure signal. All subjects will undergo 33 interventions expected to take approximately 4 - 6 hours.

研究概览

研究类型

介入性

注册 (实际的)

26

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Florida
      • Miami、Florida、美国、33126
        • Baxter Investigational Site

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 55年 (成人)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Has reviewed, understood and signed an informed consent.
  • Age between 18-55 years.
  • Body mass index between 18.5-35 kg/m2 with a minimum weight of 45 kg.
  • Willing and able to comply with study procedures and duration.
  • Subjects wearing any type of nail polish and/or acrylic nails must be willing to remove them prior to admission.

Exclusion Criteria:

  • Female subjects who are pregnant.
  • Subjects who are currently participating in, or have within the past 30 days participated in, another interventional clinical study or have used an investigational device or drug within the past 30 days.
  • Subjects with known respiratory conditions including but not limited to:

    • uncontrolled / severe asthma
    • flu / influenza
    • pneumonia / bronchitis
    • shortness of breath / respiratory distress
    • respiratory or lung surgery
    • emphysema, chronic obstructive pulmonary disease, lung disease
    • any other health condition that the Principal Investigator thinks can affect respiratory health
  • Subjects with self-reported heart or cardiovascular conditions including but not limited to:

    • hypertension
    • history of cardiovascular surgery
    • chest pain (angina)
    • heart rhythms other than a normal sinus rhythm or with respiratory sinus arrhythmia
    • previous heart attack
    • blocked artery
    • unexplained shortness of breath
    • congestive heart failure
    • history of stroke
    • transient ischemic attack
    • carotid artery disease
    • myocardial ischemia
    • myocardial infarction
    • restrictive or constrictive cardiomyopathy
    • congenital heart disease other than patent foramen ovale, repaired atrial or ventricular septal defect
    • any type of cardiac valve disease
    • history of cardiac arrhythmias
  • Self-reported health conditions as identified in the Health Assessment Form

    • diabetes
    • uncontrolled thyroid disease
    • kidney disease / chronic renal impairment
    • history of seizures (except childhood febrile seizures)
    • epilepsy
    • history of unexplained syncope
    • history of migraine attacks in the last 3 months
    • head injury within the last 2 months
    • cancer / chemotherapy
    • other known health condition should be considered upon disclosure in health assessment form
    • history of substance abuse or addiction to alcohol and or drugs within the last 12 months
  • Subjects with self-reported bleeding disorders including but not limited to:

    • hemophilia
    • von Willebrand disease
    • history of blood clots
    • history of bleeding problems
    • bruises easily with everyday activities
  • Subjects taking prescription blood thinners (like aspirin, clopidogrel, dipyridamole, or ticlopidine).
  • Subjects may be excluded at the discretion of the Investigator.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:设备可行性
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:IV line with an attached Deltran BP transducer
After device setup, subjects will be guided through a series of manipulations of the IV set while waveforms, pulse rate (PR), respiratory rate (RR) are collected at the start and stop of each test. At the end of the study, the PIVA algorithm will then be applied to the waveforms and calculated values will be compared with those from bedside monitors to understand the effect of common manipulations on the waveforms and determine most optimal conditions for capturing RR and PR through peripheral IV analysis.
An IV line with an attached Deltran BP transducer will be used together with LabChart software to record venous waveforms during various interventions. These waveforms will be processed using the PIVA algorithm and the calculated values will be compared to those from Nellcor respiratory monitor, Capnograph and cardiac telemetry monitoring.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Signal Quality Index (SQI) Score by Supine, Sitting, Standing Body Positions
大体时间:End of interventions #15 (supine for 5 minutes), #17 (sitting for 5 minutes), and #19 (standing for 5 minutes)
Ranking of subject body positions (supine, sitting, standing) based upon their impact on the venous waveform signal, from best to worst, based on the PIVA algorithm-derived SQI. Score on the scale include 0=no signal, 1=poor signal, 2=good signal. The highest percentage of time with good signal quality will be the best ranked position, and the lowest percentage of time with good signal quality will be the worst ranked position.
End of interventions #15 (supine for 5 minutes), #17 (sitting for 5 minutes), and #19 (standing for 5 minutes)

次要结果测量

结果测量
措施说明
大体时间
Agreement between PIVA algorithm-derived RR and RR measured with Capnography at Baseline
大体时间:End of 10 minute baseline
The difference of the PIVA algorithm-derived outcomes to their comparators (Capnography) under different conditions will be summarized descriptively by n, mean, median, minimum, and maximum. The 95% limit of agreement and a Bland Altman plot will also be done for these endpoints. Capnography is the monitoring of the concentration or partial pressure of carbon dioxide in the respiratory gases.
End of 10 minute baseline
Agreement between PIVA algorithm-derived RR and RR measured with Nellcor bedside monitor at Baseline
大体时间:End of 10 minute baseline
The difference of the PIVA algorithm-derived outcomes to their comparators (Nellcor) under different conditions will be summarized descriptively by n, mean, median, minimum, and maximum. The 95% limit of agreement and a Bland Altman plot will also be done for these endpoints.
End of 10 minute baseline
Agreement between PIVA algorithm-derived RR and RR measured with manual counting
大体时间:End of 10 minute baseline
The manual count value will be an average of the 2 minutes then the count is taken over. The difference of the PIVA algorithm-derived outcomes to their comparators (manual) under different conditions will be summarized descriptively by n, mean, median, minimum, and maximum. The 95% limit of agreement and a Bland Altman plot will also be done for these endpoints.
End of 10 minute baseline
Agreement between PIVA algorithm derived PR and PR measured with Nellcor bedside monitor at Baseline
大体时间:End of 10 minute baseline
The difference of the PIVA algorithm-derived outcomes to their comparators (Nellcor) under different conditions will be summarized descriptively by n, mean, median, minimum, and maximum. The 95% limit of agreement and a Bland Altman plot will also be done for these endpoints.
End of 10 minute baseline
Change in PIVA algorithm derived volume index between supine and passive leg raising positions
大体时间:End of Interventions #15 (supine for 5 minutes) and #18 (passive leg raise for 5 minutes)
The change in PIVA algorithm-derived volume index for a change in positions will be summarized descriptively by n, mean, median, minimum, and maximum.
End of Interventions #15 (supine for 5 minutes) and #18 (passive leg raise for 5 minutes)
Change in PIVA algorithm derived volume index between supine and standing positions
大体时间:End of interventions #15 (supine for 5 minutes) and #19 (standing for 5 minutes)
The change in PIVA algorithm-derived volume index for a change in positions will be summarized descriptively by n, mean, median, minimum, and maximum.
End of interventions #15 (supine for 5 minutes) and #19 (standing for 5 minutes)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2020年2月26日

初级完成 (实际的)

2020年3月21日

研究完成 (实际的)

2020年3月21日

研究注册日期

首次提交

2020年3月25日

首先提交符合 QC 标准的

2020年3月25日

首次发布 (实际的)

2020年3月27日

研究记录更新

最后更新发布 (实际的)

2021年4月1日

上次提交的符合 QC 标准的更新

2021年3月29日

最后验证

2021年3月1日

更多信息

与本研究相关的术语

其他研究编号

  • BXU544319
  • Pro00041143 (其他标识符:Advarra)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

是的

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅